William Mezzanotte
Chief Tech/Sci/R&D Officer at CSL LIMITED
Profile
Currently, William Mezzanotte is Chief Medical Officer, EVP & Head-R&D at CSL Ltd. Dr. Mezzanotte is also on the board of BELLUS Health, Inc. and University City Science Center. Dr. Mezzanotte previously was Vice President & Head-Respiratory & Inflammation at AstraZeneca Plc and Senior Vice President & Head-Therapeutic Area at C.H. Boehringer Sohn AG & Co. KG. William Mezzanotte received an undergraduate degree from Villanova University, a doctorate from the University of Pennsylvania and a graduate degree from The Johns Hopkins University.
William Mezzanotte active positions
| Companies | Position | Start |
|---|---|---|
| CSL LIMITED | Chief Tech/Sci/R&D Officer | 2018-09-30 |
University City Science Center
 University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Director/Board Member | 2020-06-18 |
Former positions of William Mezzanotte
| Companies | Position | End |
|---|---|---|
| BELLUS HEALTH | Director/Board Member | 2022-12-31 |
C.H. Boehringer Sohn AG & Co. KG
 C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | 2017-03-31 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 2015-02-28 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Chief Tech/Sci/R&D Officer | - |
Training of William Mezzanotte
| University of Pennsylvania | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Villanova University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| CSL LIMITED | Health Technology |
| Private companies | 4 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
C.H. Boehringer Sohn AG & Co. KG
C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
University City Science Center
University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Miscellaneous |
- Stock Market
- Insiders
- William Mezzanotte
